Prolexys Pharmaceuticals Report issue

For profit Phase 2
Founded: Salt Lake City UT United States (2001)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2007
NCT00528047
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

prlx 93936 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1